Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation
NCT05866575 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 136
Last updated 2024-07-10
Summary
This study aims to better understand the mechanisms of action of antidepressants, but also the neural correlates of motivation deficits. One hundred patients with a moderate to severe major depressive episode will be enrolled in this prospective multicenter study. The objective will be to predict the therapeutic response to two first-line antidepressants on the basis of an early neurocomputational assessment of motivation. Antidepressant treatment will be administered as monotherapy after randomization between two drugs: escitalopram and vortioxetine. Patients will undergo six visits and follow-up for one year. The investigators will combine computer modeling and functional MRI to identify motivational deficits and elucidate their brain correlates before initiation, after 7 days and after 6 months of treatment. 36 healthy volunteers will also be included to allow comparison with patients with depression. They will not receive any treatment.
Conditions
Interventions
- OTHER
-
escitalopram
Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
- OTHER
-
vortioxetine
Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
Sponsors & Collaborators
-
Centre Hospitalier St Anne
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-09-12
- Primary Completion
- 2026-10-12
- Completion
- 2026-11-12
Countries
- France
Study Locations
More Related Trials
-
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients
NCT01352572 ·Status: UNKNOWN ·Phase: NA
-
Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response
NCT00456430 ·Status: COMPLETED ·Phase: PHASE4
-
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
NCT00456014 ·Status: COMPLETED ·Phase: NA
-
Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
NCT00183677 ·Status: COMPLETED ·Phase: PHASE4
-
Functional Neuroimaging in Depression
NCT00343070 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression
NCT00655057 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
NCT00703742 ·Status: COMPLETED ·Phase: NA
-
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
NCT02749721 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry
NCT07074652 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
NCT02272517 ·Status: COMPLETED ·Phase: PHASE3
-
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
NCT01237275 ·Status: UNKNOWN ·Phase: NA
-
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
NCT00917059 ·Status: COMPLETED ·Phase: PHASE4
-
Transcranial Magnetic Stimulation Study of Cortical Excitability as Marker of Antidepressant Response: EXCIPSY Study
NCT03606850 ·Status: UNKNOWN ·Phase: NA
-
Imaging Predictors of Treatment Response in Depression
NCT00367341 ·Status: COMPLETED ·Phase: NA
-
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
NCT00070694 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030 ·Status: COMPLETED
-
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
NCT00432614 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
NCT01870843 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Escitalopram in Adult Patients With Major Depressive Disorder
NCT00108979 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
NCT01255787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder
NCT00613067 ·Status: COMPLETED ·Phase: NA
-
Study of Neural Responses Induced by Antidepressant Effects
NCT02674529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
NCT00109044 ·Status: COMPLETED ·Phase: PHASE3
-
Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression
NCT00824044 ·Status: COMPLETED ·Phase: PHASE4
-
Neural Responses and Dysphoria: Modulation by a Pharmacological Probe
NCT01101685 ·Status: COMPLETED ·Phase: PHASE4